Hacer Durmuş Tekçe

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

Jordi Díaz‐Manera, Priya S. Kishnani, Hani Kushlaf et al. · The Lancet Neurology · 2021 · 169 citations · Full text

Late-onset Pompe Disease, Autoimmune Disease, Clinical Infectious Disease +3

Turkish version of the Motor Function Measure Scale (MFM-32) forneuromuscular diseases: a cross-cultural adaptation, reliability, and validity study

Habibe Serap İnal, Ela Tarakçı, Devrim Tarakçı et al. · TURKISH JOURNAL OF MEDICAL SCIENCES · 2017 · 19 citations

Neuromuscular Coordination, Motor Development, Movement Biomechanics +25

The COVID-19 from Neurological Overview

Türkan Acar, Esra Demirel, Nazire Afşar et al. · Turkish Journal Of Neurology · 2020 · 18 citations · Full text

Viral Persistence, Neurovirology, Medicine +5

Expert opinion on the diagnostic odyssey and management of late-onset Pompe disease: a neurologist's perspective

Sevim Erdem‐Özdamar, Ayse Filiz Koc, Hacer Durmuş Tekçe et al. · Frontiers in Neurology · 2023 · 12 citations · Full text